Tagrisso Company: AstraZeneca Used for: Non-small cell lung cancer 2019 sales: $3.19 billion
In its fourth full year in the EGFR non-small cell lung cancer market, AstraZeneca's Tagrisso outperformed analysts' expectations and emerged as the standard-of-care option in previously untreated EGFR-mutated non-small cell lung cancer
With the Chinese market representing a potential cash cow for Tagrisso, the drug could add $1 billion in sales to its 2019 total of $3.19 billion, bringing its 2020 sales to $4.19 billion, EvaluatePharma said.
Since its approval to treat EGFR-mutated non-small cell lung cancer back in March 2017, Tagrisso has taken the market by storm. With more than $3 billion in sales in 2019, AstraZeneca's med has entrenched itself as the standard of care for previously untreated EGFR-mutated patients, AZ’s oncology business head Dave Fredrickson said in February.